1.河南中医药大学第三附属医院(河南 郑州 450000)
高宏敏,女,副主任中医师,主要从事中医内科疾病的诊治与研究工作
蔡庆春,主任技师;E-mail:cqc226@163.com
扫 描 看 全 文
高宏敏, 李建光, 刘建平, 等. 华蟾素胶囊对中晚期鼻咽癌放射治疗的增敏作用及对患者血清MIP-3α、cystatinA表达的影响[J]. 上海中医药杂志, 2021,55(7):45-49.
Hongmin GAO, Jianguang LI, Jianping LIU, et al. Radiosensitization effect of cinobufacin capsule on intermediate and advanced nasopharyngeal carcinoma and its influence on serum MIP-3α and cystatinA expression[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(7):45-49.
高宏敏, 李建光, 刘建平, 等. 华蟾素胶囊对中晚期鼻咽癌放射治疗的增敏作用及对患者血清MIP-3α、cystatinA表达的影响[J]. 上海中医药杂志, 2021,55(7):45-49. DOI: 10.16305/j.1007-1334.2021.2008028.
Hongmin GAO, Jianguang LI, Jianping LIU, et al. Radiosensitization effect of cinobufacin capsule on intermediate and advanced nasopharyngeal carcinoma and its influence on serum MIP-3α and cystatinA expression[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(7):45-49. DOI: 10.16305/j.1007-1334.2021.2008028.
目的,2,探讨华蟾素胶囊对中晚期鼻咽癌患者放射治疗的增敏作用及对血清巨噬细胞炎性蛋白-3α(MIP-3α)、半胱氨酸蛋白酶抑制剂A(cystatinA)表达的影响。,方法,2,将122例中晚期鼻咽癌患者随机分为观察组和对照组,每组61例。对照组患者行单纯放射治疗,观察组在单纯放射治疗的基础上加用华蟾素胶囊。两组疗程均为1个放射治疗周期,观察实体瘤疗效及不良反应发生情况,比较血清MIP-3α、cystatinA水平的变化情况,同时随访无进展生存期(PFS)及总生存期(OS),并采用多元线性回归进行预后影响因素分析。,结果,2,①观察组脱落2例,对照组脱落1例,最终完成试验者119例,其中观察组59例、对照组60例。②治疗后、治疗后1个月观察组总有效率分别为86.44%、77.97%,对照组分别为71.67%、60.00%;治疗后、治疗后1个月组间实体瘤疗效比较,观察组优于对照组(,P,<,0.05)。③治疗前后组内比较,两组血清MIP-3α、cystatinA水平降低(,P,<,0.05);组间治疗后比较,观察组MIP-3α、cystatinA水平低于对照组(,P,<,0.05)。④在不良反应方面,观察组鼻咽部不适程度轻于对照组(,P,<,0.05)。⑤观察组PFS显著高于对照组(χ,2,=4.266,,P,=0.039),两组OS比较,差异无统计学意义(χ,2,=0.834,,P,=0.361)。⑥Cox多因素分析结果显示,联合华蟾素治疗是鼻咽癌预后的独立保护因素。,结论,2,华蟾素可提高中晚期鼻咽癌患者放射治疗的敏感性,减轻放疗不良反应,延长患者PFS,其机制可能与调节MIP-3α、cystatinA表达有关。
Objective,2,To investigate the radiosensitization effect of cinobufacin capsule on patients with intermediate and advanced nasopharyngeal carcinoma undergoing radiotherapy and its influence on the expression of serum macrophage inflammatory protein-3α (MIP-3α) and cystatinA.,Methods,2,A total of 122 patients with intermediate and advanced nasopharyngeal carcinoma were randomly divided into observation group (,n,=61) and control group (,n,=61). Patients in the control group were administered with radiotherapy alone, while patients in the observation group were additionally administered with cinobufacin capsules besides radiotherapy. The treatment course of the two groups was one radiotherapy cycle. The therapeutic effects on solid tumors and adverse reactions were observed, and the changes of serum MIP-3α and cystatinA levels were compared. Meanwhile, the progression-free survival (PFS) and overall survival (OS) were followed up, and multiple linear regression (MLR) was used to analyze the influencing factors of prognosis.,Results,2,①There were 2 drop-out cases in the observation group and 1 drop-out case in the control group, and 119 cases finally completed the trial, including 59 cases in the observation group and 60 cases in the control group. ②The total effective rate of the observation group was 86.44% at the end of treatment and 77.97% one month after treatment, while that of the control group was 71.67% and 60.00% respectively. At the end of treatment and one month after treatment, the therapeutic effect on solid tumors in the observation group was better than that in the control group (,P,<,0.05). ③According to the intra-group comparison before and after treatment, the levels of serum MIP-3α and cystatinA in both groups decreased (,P,<,0.05); According to the inter-group comparison after treatment, the levels of MIP-3α and cystatinA in the observation group were lower than those in the control group (,P,<,0.05). ④In terms of adverse reactions, the nasopharyngeal discomfort degree in the observation group was milder than that in the control group (,P,<,0.05). ⑤The PFS of the observation group was significantly higher than that of the control group (χ,2,=4.266,,P,=0.039), but there was no significant difference in OS between the two groups (χ,2,=0.834,,P,=0.361). ⑥The results of Cox multivariate analysis showed that combined use of cinobufacin capsule and radiotherapy was an independent protective factor for the prognosis of nasopharyngeal carcinoma.,Conclusion,2,Cinobufacin can improve the radiosensitivity, reduce the adverse reactions of radiotherapy and prolong the PFS of patients with intermediate and advanced nasopharyngeal carcinoma, and its mechanism may be related to the regulation of MIP-3α and cystatinA expression.
鼻咽癌放射治疗华蟾素巨噬细胞炎性蛋白-3α半胱氨酸蛋白酶抑制剂A
nasopharyngeal carcinomaradiotherapycinobufacinMIP-3αcystatinA
付振涛,郭晓雷,张思维,等. 2014年中国鼻咽癌发病与死亡分析[J]. 中华肿瘤杂志,2018, 40(8): 566-571.
陈俊妮,袁波,杨时平,等. 高危因素联合分层法在预测N2-3M0期鼻咽癌预后的临床价值分析[J]. 中华放射肿瘤学杂志,2019, 28(12): 885-889.
PEN H, CHEN L, CHEN Y P, et al. The current status of clinical trials focusing on nasopharyngeal carcinoma: A comprehensive analysis of ClinicalTrials.gov database[J]. PLoS One, 2018, 13(5): e0196730.
王亢清,严建业,喻林华. 蟾皮的化学成分与临床应用研究进展[J]. 时珍国医国药,2009, 20(5): 1213-1214.
WEI X, SI N, ZHANG Y, et al. Evaluation of bufadienolides as the main antitumor components in cinobufacin injection for liver and gastric cancer therapy[J]. PLoS One, 2017, 12(1): 141-148.
徐泳,韩迪,冯凡超,等.华蟾素注射液联合含铂一线化疗方案治疗非小细胞肺癌的Meta分析[J]. 中国中药杂志,2019, 44(21): 4728-4737.
严科. 康莱特注射液结合华蟾素片对原发性肝癌患者姑息治疗效果分析[J]. 中国全科医学,2018, 21(S2): 182-184.
李楠静,黄娟,张又,等. 华蟾素对人胃癌SGC7901细胞增殖及RhoGTPase表达的影响[J]. 重庆医学,2018, 47(23): 12-14.
CAI Y, LI J, LU A, et al. Increased serum levels of macrophage inflammatory protein-3α and cystatin a predict a poor prognosis of nasopharyngeal carcinoma[J]. Medicine, 2014, 93(22): e123.
TANG M Z, OU N J, CHENG L, et al. Expression and prognostic significance of macrophage inflammatory protein-3 alpha and cystatin A in nasopharyngeal carcinoma[J]. Biomed Res Int, 2015, 20(15): 617143.
BREZINSKI D, STONE P H, MULLER J E, et al. Prognostic significance of the Karnofsky Performance Status score in patients with acute myocardial infarction: comparison with the left ventricular ejection fraction and the exercise treadmill test performance. The MILIS Study Group[J]. Am Heart J, 1991, 121(5): 1374-1381.
SONG P, ZHANG J C, SHANG C C, et al. Curative effect assessment of immunotherapy for non-small cell lung cancer: The “blind area” of Immune Response Evaluation Criteria in Solid Tumors (iRECIST)[J]. Thoracic Cancer, 2019, 10(5): 745-749.
韩少良. 癌症化学治疗的毒副反应及其处理[M]. 上海:复旦大学出版社,2001: 145.
KO E C, FORMENTI S C. Radiotherapy and checkpoint inhibitors: a winning new combination?[J]. Ther Adv Med Oncol, 2018, 10(7): 825-829.
POST A E M, BUSSINK J, SWEEP F C G J, et al. Changes in DNA damage repair gene expression and cell cycle gene expression do not explain radioresistance in tamoxifen-resistant breast cancer[J]. Oncol Res, 2020, 28(1): 33-40.
乜全民,郭品,郭烈美,等. 恶性胶质瘤放疗敏感性的分子机制研究[J]. 中华神经医学杂志,2014, 13(10): 1067-1069.
程鹏,王生,郭苹,等. 华蟾素胶囊联合SOX方案治疗晚期胆囊癌的临床研究[J]. 中华中医药学刊,2019,37(10):2438-2486.
倪腾洋,李丹,王海波,等. 华蟾素通过调控基质金属蛋白酶抑制人胃腺癌细胞MGC-803侵袭与迁移[J]. 中国实验方剂学杂志,2018, 24(19): 106-111.
雷金华,喻雄杰,狄全书,等. 华蟾素胶囊联合放射治疗用于中晚期鼻咽癌的临床观察[J]. 中国药房,2017, 11(5): 633-635.
CHEN P S, ZHONG Z H, JIANG H, et al. Th17-associated cytokines multiplex testing indicates the potential of macrophage inflammatory protein-3 alpha in the diagnosis of biliary atresia[J]. Cytokine, 2019, 11(6): 21-26.
CAI Y, LI J, LU A, et al. Increased serum levels of macrophage inflammatory protein-3α and cystatin a predict a poor prognosis of nasopharyngeal carcinoma[J]. Medicine, 2014, 93(22): e123.
YU X, JI M F, CHENG W M, et al. Assessment of the long-term diagnostic performance of a new serological screening scheme in large-scale nasopharyngeal carcinoma screening[J]. J Cancer, 2018, 9(12): 2093-2097.
MA Y, CHEN Y, LI Y, et al. Cystatin A suppresses tumor cell growth through inhibiting epithelial to mesenchymal transition in human lung cancer[J]. Oncotarget, 2017, 9(18): 14084-14098.
李军,汤敏中,陆爱英,等. 鼻咽癌患者血清MIP-3α与cystatin A表达及其临床意义[J]. 中国癌症杂志,2013, 23(10): 845-851.
崔殿生,熊治国,殷涛,等. 益气化毒方内服联合华蟾素膀胱灌注防治浅表性膀胱癌术后复发的研究[J]. 中国实验方剂学杂志,2014, 20(16): 204-208.
姜怡,吴立波,沈丽萍,等. 中医综合维持治疗方案对晚期非小细胞肺癌患者血清中可溶性细胞毒T淋巴细胞相关抗原4的影响及其与预后的关系[J]. 中华肿瘤杂志,2016, 38(10): 757-762.
0
浏览量
139
下载量
0
CSCD
2
CNKI被引量
关联资源
相关文章
相关作者
相关机构